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Bladder leiomyosarcoma: Partial cystectomy and complementary treatment
D. Cumplido, J. Toral, A. Soto
Hospital de Torrevieja, Oncología, Spain
Objective. We report a new case of bladder leiomyosarcoma in an elderly patient. Bladder leiomyosarcoma is an infrequent
malignancy, representing less than 1% of all bladder neoplasms. Nevertheless, among the range of mesenchymal tumors,
leiomyosarcoma is the most common lesion found in the bladder.
Methods. A 75-year-old male presented with a history of moderate chronic obstructive pulmonary disease and no other medical
antecedents of interest. The patient reported to the emergency Service with urethral bleeding and urinary retention. Since
urethral catheterization did not prove possible, a suprapubic catheter was placed, followed by evaluation of the case. Ultrasound
revealed a large distended bladder with an apparent single diverticulum of a size similar to that of the bladder itself (over
13 cm in maximum diameter), with several wall polypoid images measuring under 2–3 cm in size both in the bladder and in the
diverticulum, suggestive of a bladder neoplastic process. In view of the ultrasound ﬁndings and urethral stenosis, an ureterotomy
was performed with cystoscopy which revealed a solid calciﬁed tumor measuring almost 7 cm in size, located on the lateral wall.
Transurethral resection was performed in the same surgical intervention, leaving residual tumor.
Results. Based on these results, the decision was taken to complete surgery, opting for partial cystectomy and diverticulectomy,
with the following histological ﬁndings: Low-grade leiomyosarcoma (3 mitotic ﬁgures per 10 high-magniﬁcation ﬁelds), with
marked cellular pleomorphism. With the diagnosis of low-grade leiomyosarcoma with invasion of all the layers, the case was
evaluated by the clinical committee, which decided to provide adjuvant therapy in view of the high risk condition of the patient.
The study of disease spread was moreover completed with a chest and abdominal CAT scan, bone gammagraphy and pelvic MRI,
which showed no distant spread. Locoregional radiotherapy (dosage 57Gy) and complementary chemotherapy were provided.
Chemotherapy consisted of a combination of ifosfamide and adriamycin at the usual doses, in the form of three treatment
cycles. Following treatment, the patient was subjected to strict follow-up with periodic cystoscopy, urinary cytology and chest-
abdominal-pelvic CAT scans. After a period of 30 months, he remains free of disease
Conclusion. Bladder leiomyosarcoma is an infrequent tumor in which complete surgical resection remains the management
option of choice. Of note in the present case is the use of conservative surgery, which is regarded as feasible provided the entire
neoplasm is removed. The role of neoadjuvant chemotherapy with a view to facilitating resection or a partial cystectomy should
be evaluated in tumors of this kind. Chemotherapy and radiotherapy after partial surgical resection appears to be acceptable in
order to reduce the risk of relapse.
http://dx.doi.org/10.1016/j.rpor.2013.03.478
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Introduction. Laboratory studies have shown signiﬁcant advantages of neoadjuvant hormone therapy (HT) to radiotherapy (RT) in
prostate cancer (PC) as a result of its boosting and supra-additive effect. It also slows cell division and reduces tumor hypoxia.
Very low PSA values with HT before radiotherapy could reduce time on HT.
Objectives. To present options recommended by radiation oncologists in the most controversial aspects of treating PC using
neoadjuvant aLHRH in 4 typical patients: 2 with intermediate-risk (IR) disease and 2 with high-risk (HR) disease, with(out)
cardiovascular comorbidity.
Methods. The ÁGORA project involved 18 oncologists and comprised 4 phases: (1) selection of the most controversial issues in
treatment of PC using neoadjuvant aLHRH; (2) selection of the most relevant published scientiﬁc articles; (3) preparation of case
reports; (4) critical reading of the articles and discussion of the case reports at regional meetings (May–July 2011). Therapeutic
procedureswere classiﬁed as “highly recommendable”, “recommendable in some cases”, or “not recommendable/not applicable”.
The dispersion of the responses was considered to indicate consensus (SD<0.15) or high variability (SD>0.85).
Results. In patients with IR with(out) a cardiovascular history, HT was not recommendable in some cases (SD 0.14). Sixteen of the
18 oncologists did not agree with neoadjuvant HT. In patients with HR disease and no history of severe cardiovascular events and
>1 unfavorable risk factor, no participants rejected long-term HT (24–36 months). Half did not recommend adapting the duration
of HT to the response to neoadjuvant HT. In the HR patient aged 65 years with cardiovascular problems and >1 unfavorable risk
factor, no consensus was reached on the role of HT, although most participants (14/18) did not reject it. Ten of the 18 participants
considered that neoadjuvant HT could be administered until PSA reached <0.1. The only short-term regimen recommended in
this group was that of D’Amico (13/18).
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Conclusions. This study reveals a high degree of controversy over neoadjuvant HT in PC. HT is only accepted as part of the D’Amico
regimen.
http://dx.doi.org/10.1016/j.rpor.2013.03.479
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Resumen
Introduction and objectives. Cardiovascular mortality is the most important cause of death in prostate cancer (PC) patients. This
may partly relate to a greater risk ofmetabolic syndrome (MS) during long-term androgen deprivation therapy (ADT). The primary
objective of this analysis was to assess the prevalence of MS in men with PC before initiating ADT and after 12 months of ADT.
Materials and methods. ANAMET was an observational, prospective, multicentre, open study conducted in Spain to assess the
prevalence of MS in ADT-naïve PC patients during 12 months of treatment with quarterly gonadotropin-releasing hormone
(GnRH) agonists. MS was evaluated at baseline, 6 and 12 months after initiation of ADT. An increase of over 5% in MS prevalence
was considered clinically signiﬁcant.
Results.Of 535patients included in the study, 422 completed the study and310 completed all evaluations (per-protocol population).
In theper-protocol population,MSwasdetected in 71 (22.9%) patients at baseline and 83 (26.8%) after 12months ofADT (difference
of 3.9% and 95% CI [−0.3–8.1%]). Of the 71 patients with MS at baseline, 25 (35.2%) did not have MS after 12 months of ADT. Of
the 239 patients without MS at baseline, 37 (15.5%) had MS after 12 months of ADT.
Conclusion. Some increase in MS following 1 year of ADT with GnRH agonists was observed in this open observational study;
however, of the patients presenting with MS at baseline, there was a notable reduction in the number presenting with MS after 1
year of ADT. The prevalence of MS was high at baseline in this ADT-naïve population, suggesting that other measures unrelated
to PC therapy (such as weight control) are important for reducing the risk of MS in this population. More long-term observational
data are needed to elucidate the impact of ADT on MS.
http://dx.doi.org/10.1016/j.rpor.2013.03.480
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Purpose/objective. To retrospectively evaluate the outcomes and prognostic factors of salvage External Beam Radiotherapy (EBRT)
after Radical Prostatectomy (RP) for localized prostate cancer (PCa) with different dosing schedules.
Material/methods. Data from 159 patients referred from 4 different urology departments between 2007 and 2012, were included
in a retrospective study describing referral criteria for postoperative EBRT. From that series, 20 were referred for adjuvant-
EBRT, 9 did not receive EBRT and 8 had not a post-RP PSA. Finally 122 consecutive patients, referred for salvage-EBRT were
included in the present study. Clinical and pathological data were analyzed, including pT stage, Gleason score, margin status,
perineural invasion, pre-EBRT PSA, and EBRT dose. Clinical outcome was evaluated as Biochemical Progression-Free Survival
(BPFS). Pathological ﬁndings showed a 58.2% of pT3a-b/T4 tumours and 59% of positive margins. An undetectable level of post-RP
PSA (<0.10ng/ml) was reached by 46.7%, while a permanently detectable-PSA (PD-PSA, ≥0.10ng/ml) was present in 53.3%. The
limit of a pre-EBRT PSA ≥1ng/ml was exceeded in 41% of patients. The delivered EBRT doses were: 66Gy (17.2%), 70Gy (55.7%)
and 72–74Gy (27.1%).
Results. The median follow-up was 17 months. The probability of BPFS at 3 years was 72.4%. No differences were found in terms
of patient referral as relapsed or PD-PSA. Doses ≥72Gy were associated to increased BPFS at 3 years (89% vs. 59%; p=0.044)
compared to lower doses (66–70Gy). Higher doses were related to increased BPFS in patients meeting adjuvant-EBRT criteria
(pT3a-b/T4 or positive margins; p=0.026 and 0.002, respectively). Furthermore, patients with pre-EBRT PSA levels <1ng/ml has a
